We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Brainjuicer | BJU | London | Ordinary Share |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 787.50 | 01:00:00 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 787.50 |
| Top Posts |
|---|
Posted at 03/3/2017 21:15 by saturn5 Some of these have lovely chartsPVG BJU FARN WAND BOO We've struck gold here All those shares are 100% BUYS |
Posted at 03/3/2017 16:21 by saturn5 longshanks£10 will only be 25% from now I am following PVG WAND FARN BJU for the long |
Posted at 03/3/2017 13:53 by longshanks Welcome essential.You are in at the start of a new era that should push BJU well above £10 over the next couple of years.Don't listen to me though: I am too emotionally involved. |
Posted at 27/2/2017 17:13 by longshanks With regard to the rebranding, I would recommend watching the video in the link I posted over the weekend.I think the company know what they are doing. Having grown from a £15m outfit to a near £100m outfit, they want to reenergise the business for the next phase of growth that could well take them into the FTSE 250. They have taken soundings from their largest investors who seem wholly supportive and whilst the process is not without its risks - their core client base is small and easy to manage so should be easy to align. Overall I am excited about this next phase and the rebranding. If they can generate 30% CAGR each year for the next four years then this will become a very different company. I also love the fact that they are doing the rebrand on April fool's day! ---- Regarding your purchase price: I would forget about it. You certainly haven't bought the shares cheap, but they are fair value. Better to have bought at £7.25 than >£8 as some have. The company is throwing off cash, and without any acquisition targets in sight will be returning a lot of that cash to shareholders. If they achieve their growth targets organically, that rate of cash return is only going to accelerate. You should look at holding shares over the long term and something like BJU/SYS1 with low liquidity and a trading spread of approx. 30p really discourages any short term trading activity. |
Posted at 27/2/2017 16:07 by saturn5 longshanksThanks for that post BJU is almost down to what I paid for it |
Posted at 27/2/2017 14:55 by longshanks Investing in shares can be a painful process; there are no magic formulae for success unfortunately.Avoid buying when the market is too hot (e.g. after news releases) and wait when share prices are dropping because they will probably drop further - are my two cardinal rules.I research my stocks carefully and tend to try and buy when no-one else is buying.No advice intended, but here is:Longshanks' bakers dozenIMM - immupharma ODX - Omega diagnosticsLTG - leaning technology groupSCE - surface TransformsVLE - volvereBJU - brainjuicer FARN - faron pharmaceuticalsNFC - next fifteen communicationsSOM - somero enterprisesHUR - hurricane energyRWS - RWS holdingsPTSG - premier technical servicesSPHR - sphere medical This is in my investing order of preference. IMM has astonishing potential. It is less than a year away from completing a phase 3 trial on a drug with blockbuster potential (>$1bn sales pa). Market is gradually waking up to that potential and you can still buy in cheap. It looks like a binary option on success of this drug, but the phase 2 data was so good it has been given the FDA special protocol assessment. The chances of success are far higher than for your typical drug trial.All the others are worth researching. I don't have stakes in them all - but they are all very much on my active watch list. |
Posted at 07/2/2017 17:00 by longshanks An interesting new board appointment today in Alex Hunt. A fresh faced 35 year old; seasoned market research professional who has headed up the US business for a number of years overseeing a transformational change.Also worth noting how involved BJU were in tracking the effectiveness of advertising (in real time) during Sunday's Super Bowl.They have a big fan in Coca-cola in their processes going by this report:hTTps://www.w |
Posted at 25/1/2017 18:23 by longshanks I have a few favourite plays crazycoop although I am going to hold it in cash for the time being (my favourite asset class)I do follow stockopedia and rate their commentary.Graham Neary is a faithful follower of BJU but (as far as I know) has never bought in. The 3-year and 1-year comparison trends with NFC/YOU in the header is quite a good means of seeing current performance. Over 3 years BJU still has some way to catch up. It is though certainly outperforming the two larger companies since announcing a return to double-digit growth in December. Cannacord have given a tp of £7.20 which I feel is a little low and I can imagine some funds wanting to buy in at up to £8.The company is close to a £100m market cap. That may well result in added attention and with it better liquidity. |
Posted at 20/1/2017 08:48 by crazycoops That gap up certainly discourages people buying. But we know BJU is highly illiquid, I just hope that when the time comes, I'm not trying to exit on a profit warning. Best outcome for me with BJU is a takeover. |
Posted at 19/1/2017 17:35 by longshanks Thanks crazycoops.I thought it would be interesting to compare against NFC and YOU - so added this too as you may have noticed. NFC really has been an excellent investment with year-on-year growth since birth. YOU had a rocky few years - but it too has proven an excellent investment over the last 3 to 5 years. BJU is definitely behind the curve on both of these two larger peer companies, but it would seem it is definitely in "catch-up". The one big difference is that NFC and YOU have grown through acquisition and whilst both are strong cash generators they have financed much of that acquisition through debt. BJU has no debt and tends to return surplus cash back to shareholders. That difference in leverage could well account for the deviation in share price performance. I personally prefer the transparency of BJU's balance sheet though: it is clear at a glance whereas the balance sheets of the other two are something of a minefield. BJU has invested small amounts in new innovations - some disappear like "Digividuals" but the new investment in System1 Agency looks like it has real potential: strong on fluency to coin one of their phrases. If this new corporate branch works it will be transformational and the rate of return far higher than a more traditional acquisition would have proven. If it fails - BJU writes off £300k. That sounds like sensible, manageable risk to me. Interesting times. |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
